AMA voices cannabis concerns to feds as hemp THC ban nears

What the AMA headline confirms, and what it doesn't

Marijuana Moment reported on Nov. 3, 2026 that the AMA voiced cannabis concerns to federal officials, but the specific asks weren't available to CannIntel.

The newsletter headline is the only confirmed detail. The signal doesn't say which officials received the message, which agency it targeted, or whether it addressed marijuana, hemp-derived products, or both. We won't guess.

That gap matters. A medical society's cannabis position reads very differently depending on whether it targets the DEA, the FDA, or Congress.

Rescheduling is still the main track

The DEA's proposal to move marijuana from Schedule I to Schedule III has been pending since the Justice Department published its notice of proposed rulemaking on May 21, 2024.

An August 2023 recommendation from the Department of Health and Human Services came first. HHS concluded that marijuana has a currently accepted medical use and a lower abuse potential than Schedule I or II drugs, according to the DEA's notice.

In paraphrase: the federal health agencies' own finding that marijuana has accepted medical use is the hinge of the entire rescheduling case, which is why physician groups carry unusual weight in the debate.

A hearing before an administrative law judge, set for January 2025, was stayed, and the process has been contested since. A December 2025 executive order from President Donald Trump directed the attorney general to expedite the move, according to the order's text. CannIntel's topic hub on DEA marijuana rescheduling tracks each procedural step.

Why a physician group's voice carries weight

Schedule III status would change tax treatment and research access, but it wouldn't make state-licensed dispensary sales federally legal.

For operators, the headline benefit is relief from Section 280E, the tax provision that bars deductions for businesses trafficking in Schedule I and II substances. Schedule III would also ease the research bottlenecks that clinicians cite when they say the evidence base lags consumer use.

Medical groups tend to push on three fronts: dosing evidence, adolescent exposure, and product labeling. How the AMA framed its concerns will show whether it's urging caution on rescheduling or asking for tighter guardrails after it. Either read is plausible. Neither is confirmed.

The hemp clock runs out November 12

A federal hemp redefinition enacted in the November 2025 appropriations law takes effect on Nov. 12, 2026, shifting the legal test from delta-9 THC to total THC.

Under the old farm bill definition, hemp was capped at 0.3% delta-9 THC by dry weight. That language let high-THCA flower pass compliance testing, because THCA isn't psychoactive until heat strips off its carboxyl group through decarboxylation. Smoke it and it converts to delta-9. The conversion factor is roughly 0.877, the molecular weight ratio of THC to THCA.

Now the new definition counts total THC and caps finished products at 0.4 milligrams per container, according to the enacted text. It also targets synthesized cannabinoids, which sweeps in isomerization products such as delta-8 made from CBD.

Does the AMA's outreach touch any of this? The signal doesn't say. But the hemp-derived intoxicant market is where pediatric poisoning and labeling concerns have been loudest, so the overlap wouldn't be a surprise.

What operators should expect next

Enforcement of the new hemp definition will likely vary by state and agency, and rescheduling still lacks a final rule.

Hemp processors face a hard cutoff. Retailers holding THCA flower, vapes, and beverages need to know whether their inventory clears the per-container limit before Nov. 12. Many won't. State regulators, meanwhile, have written their own THC rules, and those don't automatically align with the federal change.

Marijuana operators face a different question: whether rescheduling arrives as a final DEA rule, a court-driven outcome, or not at all. Pressure from medical organizations could speed or slow that timeline, depending on what they actually asked for.

The next signals: the full text of the AMA's communication, any DEA or Justice Department response, and agency guidance in the days around Nov. 12. This is unsettled, and expect enforcement to vary.